ライフサイエンスコーパス: hemagglutination

1 tagenesis to identify two genes required for hemagglutination.

2 roblems that cannot be resolved by classical hemagglutination.

3 Serum anti-A antibodies were assessed by hemagglutination.

4 Loss of hemagglutination ability results in attenuation.

5 rticles (VLPs) carrying these mutations lost hemagglutination ability, showed different ganglioside s

6 ind to IAV and inhibit viral infectivity and hemagglutination activity in vitro.

7 HNPs 1 and 2 did not inhibit viral hemagglutination activity, but they interfered with the

8 le all mutants reacquired various degrees of hemagglutination activity.

9 bohydrates and glycoproteins inhibited their hemagglutination activity.

10 ayer has been isolated, and shown to mediate hemagglutination, adhesion/invasion of epithelial cell,

11 briae are characterized by mannose-sensitive hemagglutination and are assembled via the chaperone/ush

12 H binding affinity based on their effects on hemagglutination and biofilm formation along with direct

13 The striking correlation between the ranked hemagglutination and endogenous sialidase activities of

14 phorin A-specific antibodies was assessed by hemagglutination and flow cytometry.

15 Native and recombinant forms of LSL showed hemagglutination and hemolytic activity and both activit

16 in the loss of or reduced viral binding and hemagglutination and in the inability to spread among BH

17 Hemagglutination and neutralization assays indicated tha

18 The binding was demonstrated by hemagglutination and saliva binding assay using recombin

19 reviously described HA nanoparticles mediate hemagglutination and then determined that the Y98F mutat

20 hich are important for receptor recognition, hemagglutination, and membrane interaction-are in the ou

21 A) is sensitive and a CSF Treponema pallidum hemagglutination assay (CSF-TPHA) titer of >/=1:640 is s

22 An indirect hemagglutination assay (IHA) is used as a reference sero

23 ked immunosorbent assay (ELISA), an indirect hemagglutination assay (IHA), an IgM dipstick assay (LDS

24 imen, for each test was as follows: indirect hemagglutination assay (MRL Diagnostics, Cypress, Calif.

25 RPR] titer > or = 1:8 and Treponema pallidum hemagglutination assay [TPHA]/fluorescent treponemal ant

26 or = 1 :8 and a positive Treponema pallidum hemagglutination assay or indirect fluorescent treponema

27 Virus dilution (hemagglutination assay titer, 512) of 0.156 vol% was rea

28 Initially demonstrated by hemagglutination assay with human erythrocytes and intac

29 In contrast to the hemagglutination assay, the ABO-glycan microarray allows

30 3-5 d via reverse-transcription (RT)-PCR or hemagglutination assay.

31 rior exposure to B. pseudomallei by indirect hemagglutination assay.

32 Hemagglutination assays and quantitative precipitation a

33 The assays included hemolytic and hemagglutination assays and the measurement of immunoglo

34 tional characterization of the protein using hemagglutination assays revealed lectin activity.

35 noassays with anti-type 1 pilus antibody and hemagglutination assays showed that fewer type 1 pili we

36 interpreting anti-ABO antibodies measured by hemagglutination assays with reagent erythrocytes.

37 Hemagglutination assays, receptor-destroying enzyme acti

38 using molecular assays, virus isolation, and hemagglutination assays.

39 city of glycan binding was confirmed through hemagglutination assays; GST-VP8* P[11] hemagglutinates

40 ell, and monocyte responses) correlated with hemagglutination at day 28.

41 A hemagglutination-based assay with E. coli expressing mut

42 l deletion mutant of LSLa (LSLa-D1) retained hemagglutination, but not hemolytic activity, indicating

43 could block carbohydrate binding and inhibit hemagglutination by NV rVLP.

44 2005 to 2009 has been the poor inhibition of hemagglutination by postinfection ferret antisera for ma

45 damage and increased in vitro inhibition of hemagglutination by SP-D.

46 The T3-specific antibody inhibited hemagglutination by T3 virions but not ISVPs, indicating

47 ad range of H7 subtype viruses and inhibited hemagglutination by the novel H7 hemagglutinin.

48 The T1-specific antibody inhibited hemagglutination by virions and ISVPs, probably via dire

49 The mutant library was screened for hemagglutination deficiency, and three clones were isola

50 d as G in virus designations) and either the hemagglutination (HA [H]) or the nucleoprotein (NP [P])

51 s by electron microscopy; however, its viral hemagglutination (HA) activity was not inhibited by anti

52 gut mucosa as well as RBCs, we used rNV VLP hemagglutination (HA) as a model system for studying NV

53 say and submicromolar cellular activity in a hemagglutination (HA) functional cell assay of bacterial

54 f measuring ABO antibody levels based on the hemagglutination (HA) titers have the disadvantages of r

55 (HN) is a multifunctional protein mediating hemagglutination (HA), neuraminidase (NA), and fusion pr

56 to sialic acid and inhibits reovirus-induced hemagglutination (HA).

57 Indirect hemagglutination (IHA) is typically used to serotype thi

58 esidues that are required for CFA/I-mediated hemagglutination, implicating this as the receptor-bindi

59 -2,3-didehydro-N-acetylneuraminate inhibited hemagglutination in a pattern correlated with endogenous

60 mune response (alloantibody) was detected by hemagglutination in the serum of a transfused patient.

61 Subjects had minimal pre-existing hemagglutination inhibiting (HAI) antibodies and TIV ind

62 les virus (neutralizing antibody) and HPIV3 (hemagglutination inhibiting antibody) of over 1:500.

63 viruses that we tested raised high levels of hemagglutination-inhibiting (1:160-1:1280) and virus-neu

64 -49 years and 50-70 years) with undetectable hemagglutination-inhibiting (HAI) antibody to H7N9 were

65 Hemagglutination-inhibiting (HI) antibodies and cellular

66 ation activity, but they interfered with the hemagglutination-inhibiting activity of SP-D.

67 day after infection, followed in 1-2 days by hemagglutination-inhibiting and neutralizing antibodies.

68 ts but not control subjects generated strong hemagglutination-inhibiting and neutralizing antibody re

69 y distant H1N1 strains than the conventional hemagglutination-inhibiting and neutralizing MAbs.

70 otein preparations from both lineages raised hemagglutination-inhibiting antibodies against H7N9 viru

71 none of these sera had detectable levels of hemagglutination-inhibiting antibodies against the H7N9

72 YF hemagglutination-inhibiting antibodies appeared 4 or 5 d

73 virus (HIV) infection and the persistence of hemagglutination-inhibiting antibodies in mothers and in

74 , a RIG-I ligand, developed robust levels of hemagglutination-inhibiting antibodies, enhanced germina

75 Comparison of hemagglutination-inhibiting geometric mean titers to inf

76 uated ones, developed higher levels of HPIV3 hemagglutination-inhibiting serum antibodies than did mo

77 oteins (X1, X3, X6, and P1) had the broadest hemagglutination inhibition (HAI) activity against a pan

78 g COBRA HA proteins elicited antibodies with hemagglutination inhibition (HAI) activity against more

79 Hemagglutination inhibition (HAI) and microneutralizatio

80 he subsets of study subjects assessed, serum hemagglutination inhibition (HAI) and nasal-wash antihem

81 Rates of hemagglutination inhibition (HAI) and neuraminidase inhi

82 Serum hemagglutination inhibition (HAI) and neutralizing (Neut

83 a secondary analysis of a subset of infants, hemagglutination inhibition (HAI) antibodies were measur

84 /95 was more likely to induce cross-reactive hemagglutination inhibition (HAI) antibody against A/Tex

85 ine trials, we assessed their cross-reactive hemagglutination inhibition (HAI) antibody responses aga

86 Hemagglutination inhibition (HAI) antibody responses to

87 erase chain reaction (RT-PCR), and the serum hemagglutination inhibition (HAI) antibody titer, were a

88 Adverse reactions were assessed, and hemagglutination inhibition (HAI) antibody titers were d

89 Antibodies were measured by hemagglutination inhibition (HAI) assay at baseline, 21-

90 The hemagglutination inhibition (HAI) assay is the primary m

91 Immune responses were measured with a hemagglutination inhibition (HAI) assay, and influenza w

92 ated influenza vaccine (LAIV) were tested by hemagglutination inhibition (HAI) assay, microneutraliza

93 Vaccine responses were analyzed using hemagglutination inhibition (HAI) assays.

94 Antibody titers measured by hemagglutination inhibition (HAI) correlate with protect

95 There was no hemagglutination inhibition (HAI) cross-reactivity in fe

96 Hemagglutination inhibition (HAI) geometric mean titers

97 Anti-minor subunit Fab preparations showed hemagglutination inhibition (HAI) of ETEC expressing hom

98 ost effective regimens elicited the broadest hemagglutination inhibition (HAI) response against a pan

99 nin could not be detected after infection by hemagglutination inhibition (HAI) test with avian and se

100 showed an improved response, with a positive hemagglutination inhibition (HAI) titer in 91% of recipi

101 A serum hemagglutination inhibition (HAI) titer of 40 or greater

102 C-Ad produced markedly higher HA binding and hemagglutination inhibition (HAI) titers than RD-Ad in S

103 ntibody responses, especially IgA levels and hemagglutination inhibition (HAI) titers, more than 8-mo

104 fluenza-specific antibodies were measured by hemagglutination inhibition (HAI), and T cells were stud

105 lack of antibody cross-reactivity to ICV in hemagglutination inhibition (HI) and agar gel immunodiff

106 Hemagglutination inhibition (HI) and gene sequencing exp

107 ationally designed ancestral H5N1 strains by hemagglutination inhibition (HI) and microneutralization

108 When evaluated by hemagglutination inhibition (HI) and microneutralization

109 by sera diluted 1:5 or 1:10 correlated with hemagglutination inhibition (HI) and microneutralization

110 al evidence of infection based on results of hemagglutination inhibition (HI) and microneutralization

111 The H10-directed MAbs displayed functional hemagglutination inhibition (HI) and neutralization acti

112 lities of H1 HA and H3 HA antigens to elicit hemagglutination inhibition (HI) and neutralizing antibo

113 Viruses were characterized by hemagglutination inhibition (HI) and sequencing of antig

114 correlated with antibody titers measured by hemagglutination inhibition (HI) and virus microneutrali

115 seasonal influenza vaccine (TIV) can affect hemagglutination inhibition (HI) antibody responses to p

116 9 shedding, although the LAIV elicited lower hemagglutination inhibition (HI) antibody titers in seru

117 Hemagglutination inhibition (HI) antibody titers were me

118 Antibody to H3N2v was assessed by hemagglutination inhibition (HI) assay and, for a subset

119 Hemagglutination inhibition (HI) assay data for swine an

120 n of influenza viruses is typically based on hemagglutination inhibition (HI) assay data for viral is

121 in restoring the anti-HA specificity of the hemagglutination inhibition (HI) assay for monitoring an

122 activity between influenza strains using the hemagglutination inhibition (HI) assay.

123 ce of seropositivity (titer >/=40) using the hemagglutination inhibition (HI) assay.

124 Antigenic drift is assessed primarily by the hemagglutination inhibition (HI) assay.

125 chicken eggs and hemagglutinin subtyping by hemagglutination inhibition (HI) assay.

126 erum antibody responses were determined by a hemagglutination inhibition (HI) assay.

127 eir antigenic characteristics as measured by hemagglutination inhibition (HI) assay.

128 As predicted, hemagglutination inhibition (HI) assays using human sera

129 dividuals using microneutralization (MN) and hemagglutination inhibition (HI) assays.

130 d by microneutralization assays and modified hemagglutination inhibition (HI) assays.

131 t of these introduced substitutions by using hemagglutination inhibition (HI) data with monovalent sw

132 reened a large panel of HA-specific MAbs for hemagglutination inhibition (HI) in the presence of noni

133 2009 to September 2010) were tested using a hemagglutination inhibition (HI) test.

134 Antigenic analysis by hemagglutination inhibition (HI) tests with ferret and c

135 lear differences between individuals with no hemagglutination inhibition (HI) titers (<1:10) and thos

136 ines are able to induce antibodies with high hemagglutination inhibition (HI) titers and completely p

137 In post hoc analyses, hemagglutination inhibition (HI) titers measured at base

138 high virus neutralization titers, but their hemagglutination inhibition (HI) titers were usually low

139 In addition to hemagglutination inhibition (HI) titers, we used H1N1pdm

140 Viruses were characterized by hemagglutination inhibition (HI), and the hemagglutinin

141 accines induce low or undetectable titers of hemagglutination inhibition (HI), cross-HI, and/or virus

142 The humoral response was measured by the hemagglutination inhibition (HI), microneutralization (M

143 r immune responses to the virus, assessed in hemagglutination inhibition (HI), microneutralization, E

144 ative vaccine efficacy (VE), immunogenicity (hemagglutination inhibition [HAI] titers), and safety am

145 ological potency in chickens (geometric mean hemagglutination inhibition [HI] titers, >/= 1:169), but

146 Prevaccination hemagglutination inhibition Ab titer was <1:20 in all ex

147 influenza virus, with significant levels of hemagglutination inhibition activities (>1:40), which we

148 ng MAb previously described, MAb 6F12 has no hemagglutination inhibition activity against influenza A

149 hese five naturally occurring MAbs displayed hemagglutination inhibition activity, suggesting specifi

150 protein and neutralize virus but do not have hemagglutination inhibition activity.

151 primary outcome was geometric mean titers of hemagglutination inhibition after influenza vaccination.

152 ymptoms, and antiinfluenza antibody titer by hemagglutination inhibition after vaccination.

153 cinated pigs developed significant levels of hemagglutination inhibition and enzyme-linked immunosorb

154 Hemagglutination inhibition and immunoglobulin isotype p

155 e basis of immunologic data sets (i.e., from hemagglutination inhibition and microneutralization assa

156 rologous H2 influenza viruses as measured by hemagglutination inhibition and microneutralization assa

157 odies to H5 and H7 were measured by means of hemagglutination inhibition and microneutralization assa

158 Vietnam/1203/04 vaccine may result in higher hemagglutination inhibition and microneutralization GMTs

159 g seronegative for these viruses in standard hemagglutination inhibition and microneutralization sero

160 e end of the influenza season for testing by hemagglutination inhibition and neuraminidase inhibition

161 Hemagglutination inhibition and neutralization assays th

162 ponses and the geometric mean titer of serum hemagglutination inhibition and neutralizing antibodies

163 ch virus induced high titers of NDV-specific hemagglutination inhibition and serum neutralizing antib

164 nt trimeric NCRD, D325A/R343V, showed marked hemagglutination inhibition and viral neutralization, wi

165 Serologic analysis using hemagglutination inhibition and virus neutralization tes

166 Hemagglutination inhibition antibodies were minimal afte

167 We performed hemagglutination inhibition antibody (HI) assays on pres

168 Proportions achieving a hemagglutination inhibition antibody (HIA) titer of 40 o

169 fect of additional vaccinations, the GMTs of hemagglutination inhibition antibody after the first, se

170 In both age groups, hemagglutination inhibition antibody geometric mean tite

171 cinations (P< .001) geometric mean titers of hemagglutination inhibition antibody in vaccines with an

172 S03-adjuvanted CC-H5N1 elicited a homologous hemagglutination inhibition antibody response that satis

173 The complete absence of specific hemagglutination inhibition antibody response to A(H3N2)

174 Serum hemagglutination inhibition antibody responses were more

175 en at 21-day intervals and serum samples for hemagglutination inhibition antibody responses were obta

176 eactivity of vaccination-induced H3-specific hemagglutination inhibition antibody responses, and cons

177 Eleven of 15 (73%) employees had baseline hemagglutination inhibition antibody titers >/=40 to swi

178 r) at 1 month postvaccination based on serum hemagglutination inhibition antibody titers against each

179 hat Ban/AF induced higher neutralization and hemagglutination inhibition antibody titers against the

180 Serum hemagglutination inhibition antibody titers against the

181 A single vaccine dose produced higher hemagglutination inhibition antibody titers at day 21 in

182 ers with correspondingly low levels of serum hemagglutination inhibition antibody titers in pheasants

183 ogenicity was assessed by measurement of the hemagglutination inhibition antibody titres in serum for

184 in the geometric mean titers (GMTs) of serum hemagglutination inhibition antibody were observed when

185 uenza virus-specific immunoglobulin G (IgG), hemagglutination inhibition antibody, mucosal antibody,

186 The primary immunogenicity outcome was hemagglutination inhibition assay (HAI) titer against ea

187 as antibody titers of 1:40 or greater on the hemagglutination inhibition assay 21 to 28 days after va

188 in-specific antibody responses with standard hemagglutination inhibition assay and by memory B-cell e

189 anted influenza vaccine underwent testing by hemagglutination inhibition assay for strains not presen

190 city of influenza vaccination exclusively by hemagglutination inhibition assay may be misleading in i

191 Hemagglutination inhibition assay titers were measured b

192 Here we use the hemagglutination inhibition assay to analyze the antibod

193 in a subset of subjects were determined by a hemagglutination inhibition assay to determine the subje

194 Horse erythrocyte hemagglutination inhibition assay was performed to detec

195 A hemagglutination inhibition assay was used to assess the

196 A hemagglutination inhibition assay was used to quantify h

197 ncy of antibody response (82% vs 50%, by the hemagglutination inhibition assay) and a significantly h

198 ion rates after dose 3, assessed by means of hemagglutination inhibition assay, after adjustment for

199 Humoral responses were evaluated by a hemagglutination inhibition assay, and memory B-cell res

200 l confirmation of measles was done either by hemagglutination inhibition assay, complement fixation a

201 evaluated for their antigenic relatedness by hemagglutination inhibition assay, showing that the anti

202 Antibody titers were determined by the hemagglutination inhibition assay, using egg- and cell-d

203 atedness was assessed by gene sequencing and hemagglutination inhibition assay.

204 old rise in serum antibody titer measured by hemagglutination inhibition assay.

205 ies that are not detected in the traditional hemagglutination inhibition assay.

206 ross-reactive human antibodies detected by a hemagglutination inhibition assay.

207 tibody responses were determined by means of hemagglutination inhibition assay.

208 timmunization sera underwent strain-specific hemagglutination inhibition assay.

209 posure to influenza was determined using the hemagglutination inhibition assay.

210 mum 4-fold increase to titer >/=40) with the hemagglutination inhibition assay; vaccine-related serio

211 osomes competitively bind influenza virus in hemagglutination inhibition assays and inhibit infection

212 Hemagglutination inhibition assays and sequencing of the

213 antibody concentrations were measured using hemagglutination inhibition assays before immunization,

214 receptor and antibody binding, we conducted hemagglutination inhibition assays using virions and ISV

215 In hemagglutination inhibition assays, 12 antisera cross-re

216 ssays (26.3% and 15.8% by neutralization and hemagglutination inhibition assays, respectively).

217 h ferret antisera against MN/10 and BJ/92 in hemagglutination inhibition assays.

218 les were tested with microneutralization and hemagglutination inhibition assays.

219 an H5N1 influenza virus in neutralization or hemagglutination inhibition assays.

220 as assessed by genomic sequence analysis and hemagglutination inhibition assays.

221 Hemagglutination inhibition experiments suggested that t

222 ax)), relative affinity (K(a)), and level of hemagglutination inhibition in the plasma.

223 thermal titration microcalorimetry (ITC) and hemagglutination inhibition measurements demonstrate tha

224 atistically significant difference in day 42 hemagglutination inhibition seroconversion after mixing

225 coprimary endpoints for noninferiority were hemagglutination inhibition seroconversion rates and pos

226 viruses and vaccines from partially revealed hemagglutination inhibition table.

227 cities by blocking assays; (iv) to develop a hemagglutination inhibition test using buccal cells from

228 ding site on mutant HNs was confirmed by the hemagglutination inhibition test, which uses an inhibito

229 0,000-fold less sensitive to the compound in hemagglutination inhibition tests than rSeV(hPIV-1HN).

230 f) to the selective HN inhibitor BCX 2855 in hemagglutination inhibition tests, and slowed its growth

231 try workers were positive (on the basis of a hemagglutination inhibition titer of >/= 80) for this su

232 immunoglobulin G1 (IgG1) subclass and a high hemagglutination inhibition titer.

233 etermined based on established criterion for hemagglutination inhibition titer; participants with a h

234 Subjects with prevaccination hemagglutination inhibition titers <10 and children 3-<9

235 ated antigenic maps based on postvaccination hemagglutination inhibition titers against representativ

236 s vaccination elicited similar serum IgG and hemagglutination inhibition titers and 100% protection a

237 Significantly higher (3-5 fold) hemagglutination inhibition titers and high serum neutra

238 ease in the rates of seroconversion and mean hemagglutination inhibition titers at day 28 after vacci

239 ited influenza-specific T-cell responses and hemagglutination inhibition titers in response to an MF5

240 The study endpoint was the development of hemagglutination inhibition titers to the strain-specifi

241 Hemagglutination inhibition titers were measured at entr

242 Hemagglutination inhibition titers were sustained for 1

243 ed vaccine also leads to increased levels of hemagglutination inhibition titers, enhanced mucosal imm

244 nfluenza vaccine-specific immunity including hemagglutination inhibition titers, IgA(+) and IgG(+) Ab

245 levels of recall immune responses, including hemagglutination inhibition titers, neutralizing antibod

246 tion rate (anti-influenza antibody titers by hemagglutination inhibition) 21 d after vaccination.

247 assays, receptor-destroying enzyme activity, hemagglutination inhibition, and fluorescence focus neut

248 cytometry and vaccine antibody responses by hemagglutination inhibition.

249 d for H5 antibody by microneutralization and hemagglutination inhibition.

250 Serum samples were tested for hemagglutination-inhibition (HAI) antibody increase and

251 Changes in the hemagglutination-inhibition (HAI) antibody titer were as

252 We examined hemagglutination-inhibition (HAI) antibody titers in sub

253 Here, we performed hemagglutination-inhibition (HAI) assays, using sera col

254 d intramuscular groups, and all subjects had hemagglutination-inhibition (HAI) titers of at least 1:4

255 10), low (GMT = 28.3), or high (GMT > 761.1) hemagglutination-inhibition (HAI) titers to the A/Viet N

256 Hemagglutination-inhibition (HAI) titers were measured i

257 ficantly enhanced cellular immune responses, hemagglutination-inhibition (HAI) titers, and neutraliza

258 shared strains (A/H3N2 and A/H1N1) based on hemagglutination-inhibition (HI) antibodies 28 days afte

259 n and young adults had the highest levels of hemagglutination-inhibition (HI) antibodies to 2010-2011

260 say, and antibody responses were measured by hemagglutination-inhibition (HI) assay.

261 m samples did not react with Viet/1203/04 in hemagglutination-inhibition (HI) or virus-neutralization

262 Vaccination history, hemagglutination-inhibition (HI) titers, and cell-mediat

263 serious adverse events), and immunogenicity (hemagglutination-inhibition [HAI] titers) were performed

264 Safety and immunogenicity (by hemagglutination-inhibition [HI] assay) after each dose

265 Preseason hemagglutination-inhibition and neuraminidase-inhibition

266 Hemagglutination-inhibition and neuraminidase-inhibition

267 The ELISA was compared to hemagglutination-inhibition and plaque reduction neutral

268 letely cleared from nasal samples, and serum hemagglutination-inhibition antibodies were still undete

269 ngle dose, the geometric mean titer (GMT) of hemagglutination-inhibition antibody in primed subjects

270 on of participants achieving seroprotection (hemagglutination-inhibition antibody titer >/=1:40 on da

271 rotection and seroconversion rates and lower hemagglutination-inhibition antibody titer geometric mea

272 de 2 HA H5N1 virus-like particles (VLPs) had hemagglutination-inhibition antibody titers that recogni

273 participants had > or = 4-fold increases in hemagglutination-inhibition antibody, and 79% had > or =

274 odies to A(H1N1)pdm09 virus were measured by hemagglutination-inhibition assay in individuals with pa

275 Hemagglutination-inhibition assays were performed 28 day

276 In hemagglutination-inhibition assays, G4-SA was found to i

277 Microneutralization (MN) and hemagglutination-inhibition geometric mean titers (GMTs)

278 ubjects achieved the predetermined endpoint (hemagglutination-inhibition titer > or =40) 28 days afte

279 s reached 1:40 or greater in 54 percent, and hemagglutination-inhibition titers reached 1:40 or great

280 ally increased by PC nanogel, with increased hemagglutination-inhibition titers, CTL activity, and ea

281 Hemagglutination mediated by either type 1 or P pili, ad

282 Each hemagglutination-negative (HA(-)) cooA mutant was examin

283 e thiols in F protein when expressed without hemagglutination-neuraminidase (HN) protein but decrease

284 igenic analysis, have been assessed by virus hemagglutination of erythrocytes from different species

285 characteristically mediate mannose-sensitive hemagglutination of guinea pig erythrocytes.

286 diate (i) invasion of epithelial cells, (ii) hemagglutination of rabbit erythrocytes, (iii) interbact

287 Hemagglutination of some F. nucleatum strains is also ga

288 No hemagglutination or cellular adherence properties were d

289 to A/B/O antigens by synthetic HBGA binding, hemagglutination, or saliva binding assays.

290 e fimbriae are associated with adherence and hemagglutination phenotypes in EHEC O157:H7.

291 protein possessed immunoglobulin binding and hemagglutination properties that appeared to be based on

292 tem with uniquely integrated surface display hemagglutination (sdHA) antigen and yEGFP reporters.

293 effects on the two red cell species used in hemagglutination, suggesting that these residues play a

294 nation inhibition titer; participants with a hemagglutination titer >/=1:40 plus a >/=4-fold increase

295 In vitro tests, including hemagglutination, tracheal ring binding, and serum sensi

296 etection was significantly improved to 0.032 hemagglutination unit due to the high affinity and high

297 Two definitions of seroprotection (40 hemagglutination units (HAU) and 160 HAU which confers a

298 ic production of hemagglutinin (expressed in hemagglutination units per 10(6) cells) from the siat7e-

299 ithin 1h with a detection limit of 2(-9)HAU (hemagglutination units).

300 In contrast, G4-SA had no ability to inhibit hemagglutination with H2N2 subtypes or 2 of 5 H1N1 subty